Two major advances for CAR T-cell cancer treatment – 6abc.com
6abc.com |
Two major advances for CAR T-cell cancer treatment
6abc.com The Food and Drug Administration has expanded its approval for Kymriah, the personalized cancer immunotherapy developed at the University of Pennsylvania. The new approval is for adult patients with non-Hodgkins lymphoma – large B-cell lymphoma which … Kymriah® (tisagenlecleucel), first-in-class CAR–T therapy from Novartis, receives second FDA approval to treat … FDA approves CAR T therapy for large B-cell lymphoma FDA approves CAR T therapy for large B-cell lymphoma developed at Penn |
